Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYNAPET: Dynamic PET/CT for Neoadjuvant Pembrolizumab + Chemo in NSCLC
NCT04586465Phase 2Unknown
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Oct 2020
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04586465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586465.